volume 29, issue 6, P850-858 2015
DOI: 10.3109/02688697.2015.1056090
View full text
|
Sign up to set email alerts
|
Share

Abstract: The standard treatment for Glioblastoma Multiforme (GBM) remains maximal safe surgical resection. Here, we evaluated the ability of a systemically administered antibody-dye probe conjugate (cetuximab-IRDye 800CW) to provide sufficient fluorescent contrast for surgical resection of disease in both subcutaneous and orthotopic animal models of GBM. Multiple luciferase positive GBM cell lines (D-54MG, U-87MG, U-251MG; n=5) were implanted in mouse flank and tumours fluorescently imaged daily using a closed-field N…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
28
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals